UROVANT SCIENCES LTD. Inactive Instrument
Urovant Sciences Ltd.
Equities
UROV
BMG9381B1081
Biotechnology & Medical Research
Presenter SpeechEric Joseph (Analysts)All right. We'll get started here. Good afternoon. I'm E...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Urovant Sciences Ltd. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for a range of urologic conditions. The Company's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company's second product candidate, URO-902, is a gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.81% | 118B | |
| +10.09% | 106B | |
| -11.88% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.67% | 15.97B | |
| +6.18% | 14.03B | |
| +14.88% | 11.67B |
